Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can facing symptoms Head-On boost therapy for chronic physical distress?

NCT ID NCT07757854

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial asks whether adding structured exposure exercises to response prevention—a core part of exposure therapy—makes a meaningful difference for people who are highly bothered by persistent physical symptoms. About 360 adults with high symptom burden will be randomly assigned to receive either response prevention alone or response prevention plus exposure exercises. The study tracks changes in symptom reactivity week by week to see if the extra exposure component improves outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Behavioral therapy: exposure exercises and response prevention
What this could lead to
If successful, this could refine exposure-based treatments for people with persistent physical symptoms, making therapy more effective and targeted.
What could go wrong
The trial is early-stage and the benefit of adding exposure exercises is uncertain. Results may not apply to all patients, and therapy requires active participation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 360 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Bothered by at least one somatic symptom for at least 4 months. * High symptom burden, defined as a PHQ-15≥15 or SSD-12≥25. * Adult (≥18 years old). * Living in Stockholm County (catchment area of the clinic). * Sufficient technical knowledge with web-enabled device and fluent in Swedish. * Complete pre-treatment assessment. Exclusion Criteria: * A maximum of half the sample (180 participants) will be included with health anxiety, i.e., a fear of or preoccupation with serious illness, as their principal clinical problem. * Clinical picture dominated by non-somatoform psychiatric disorder such as depression, panic disorder, or primary insomnia. Comorbidities are allowed. * Severe psychiatric condition (e.g., ongoing manic episode, psychotic disorder, severe depression) or markers for suicidality beyond sporadic ideation. * Clear medical risk in taking part in exposure-based treatment (e.g., pregnancy), or somatic condition, or treatment for somatic condition, makes treatment unfeasible. * Continuous psychotropic medication (antidepressants, anticonvulsants, mood-stabilizers, antipsychotics) is present and has either not been stable for at least 4 weeks, or is not expected to remain stable. * Other psychotherapy or planned absence \>1 week during intended main phase.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bodily distress disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Medically Unexplained Symptoms Neurasthenia physiological malfunction arising from mental factor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Liljeholmen University Primary Health Care Centre

    Stockholm, 117 63, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.